Form 4: Day One Biopharmaceuticals Executive Charles N. York II Reports Stock Option and Restricted Stock Unit Grants

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• On January 15, 2025, Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., was granted stock options and restricted stock units (RSUs).
• York acquired options to purchase 162,000 shares of common stock at an exercise price of $11.87 per share.
• These options vest monthly over 48 months, starting February 15, 2025, contingent upon continued service to the company.
• York also acquired 106,000 RSUs, each representing a right to receive one share of Day One Biopharmaceuticals' common stock upon settlement.
• The RSUs vest quarterly over 16 quarters, beginning February 15, 2025, also contingent upon continued service.
• The reporting person directly owns 162,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the executive and the company's future prospects. However, the value is contingent on future performance.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Day One Biopharmaceuticals' stock price, which is subject to market risks and company-specific factors.

Future Outlook

The vesting of the stock options and RSUs is contingent upon the reporting person's continued service to the issuer.

Industry Context

Stock options and RSUs are common forms of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen commonly use similar equity-based compensation to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to ensure long-term commitment and performance.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the executive's performance leads to stock price appreciation.
• Employees: May boost morale as it shows the company is investing in its leadership.

Key Dates